Skip to main content
Premium Trial:

Request an Annual Quote

Olink Bioscience, Molecular Devices, Millipore, IDBS

Premium
Olink Bioscience this week previewed its DuoLink reagent kit at the annual meeting of the American Association of Cancer Research in Los Angeles and the annual meeting of the European Society of Clinical Investigation in Uppsala, Sweden.
 
DuoLink, which is scheduled for commercial launch in the second quarter, comprises DNA-tagged antibodies and fluorescently labeled oligonucleotides and is based on the company’s in situ Proximity Ligation Assay.
 
The company said that in situ PLA can detect single molecular events such as protein interactions and modifications without the use of artificially stimulated or genetically modified cells. The method is applicable to the study of signaling pathways involved in tumorigenesis, “as well as a means of quantifying the response to anti-cancer drugs and other questions of interest in high-content screening applications,” the company said.
 

 
Molecular Devices, a division of MDS Analytical Technologies, released several new products at the Society for Biomolecular Sciences conference this week in Montreal. The first, a new aequorin option for its FLIPR Tetra fluorometric imaging plate reader, includes a new camera that can detect both fluorescence and aequorin luminescence. The addition also includes a new cell suspension option.  
 
The company said that the new aequorin option enables cell suspension assays, which minimizes cell preparation time and reduces assay costs.
 
The company also launched a live cell Neurotransmitter Transporter Uptake Assay Kit, which screens for live cell kinetic uptake of dopamine, norepinephrine, and serotonin.
 
This assay uses a masking dye to extinguish extracellular fluorescence. Molecular Devices said it exclusively licensed the masking dye technology from Bayer AG.
 

 
Millipore has added the human L-type calcium channel to its CardiacProfiler service for compound liability testing. The company said it has added the PrecisION hCav1.2 recombinant cell line, which “has been developed and validated to meet biophysical and pharmacological properties of the L-type calcium channel found in the human heart.”
 
The CardiacProfiler service offers compound profiling against the L-type calcium channel assessed either as a stand alone service or as part of a panel of other cardiac ion channels, including hERG, Nav1.5, KCNQ1/minK, Kv1.5, Kv4.3/KChIP1, and HCN4. 
 

 
IDBS has launched ActivityBase XE v7.0, which includes support for complex assay types, such as multiplexing and high-content screening, the company said.
 
ActivityBase XE includes new multiple curve fitting functionality and visualization tools and provides a "single environment for data capture, visualization, verification, quality control, and storage," the company said.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.